How should colchicine be tapered after a pericardial window in an adult with recurrent pericarditis?

Colchicine Taper Post-Pericardial Window

Tapering colchicine after pericardial window is not mandatory, but if performed, reduce to 0.5 mg every other day (for patients <70 kg) or 0.5 mg once daily (for patients ≥70 kg) during the final weeks of a minimum 6-month treatment course. 1

Treatment Duration and Tapering Strategy

For recurrent pericarditis requiring pericardial window (a surgical intervention indicating refractory disease), colchicine should be continued for at least 6 months at weight-adjusted maintenance doses 1:

• Patients <70 kg: 0.5 mg once daily
• Patients ≥70 kg: 0.5 mg twice daily

Tapering Approach (If Chosen)

The 2015 ESC Guidelines explicitly state that tapering colchicine is not necessary 1. However, if tapering is considered to prevent symptom persistence and recurrence, the recommended approach is 1:

• Patients <70 kg: Reduce to 0.5 mg every other day in the final weeks
• Patients ≥70 kg: Reduce to 0.5 mg once daily in the final weeks

Critical Prerequisites Before Any Tapering

Do not attempt tapering unless BOTH conditions are met 1:

1. Complete symptom resolution (no chest pain, no pericardial friction rub)
2. CRP normalization (inflammatory markers must be normal)

Sequential Tapering Protocol

When tapering multiple medications, stop only one drug class at a time before discontinuing colchicine 1. The recommended sequence is:

1. First taper NSAIDs/aspirin (decrease by 250-500 mg every 1-2 weeks) 1
2. Then taper corticosteroids if used (very slowly, especially below 15 mg/day prednisone) 1
3. Finally, consider tapering colchicine last, over several months in difficult cases 1

Special Considerations for Post-Surgical Pericarditis

Patients requiring pericardial window represent a refractory population with higher risk of recurrence. For these patients:

• Longer treatment duration (>6 months) should be strongly considered based on clinical response 1
• Monitor CRP levels to guide treatment duration 1
• In the most difficult cases, colchicine may need to be discontinued gradually over several months 1

Common Pitfall to Avoid

If symptoms recur during tapering, do NOT increase corticosteroid doses. Instead 1:

• Maximize NSAID/aspirin doses (distributed every 8 hours)
• Ensure colchicine is at full therapeutic dose
• Add analgesics for pain control
• Consider IV NSAIDs if necessary

Monitoring During and After Taper

• CRP levels: Check before each dose reduction 1
• Symptom assessment: Any chest pain or pericardial symptoms should halt tapering
• Recurrence risk: Recurrences are possible after discontinuation of each drug 1

Safety Profile

Colchicine is generally well-tolerated at these doses. The most common side effects are gastrointestinal (diarrhea, abdominal pain), occurring in approximately 9% of patients 2. Treatment discontinuation due to adverse events occurs in a minority of cases 3, 4.

Evidence Quality Note

The guideline recommendations are based on Class I, Level A evidence for colchicine use in recurrent pericarditis 1, though specific tapering protocols are based on expert consensus (Level C evidence) 1. The evidence consistently shows colchicine reduces recurrence rates by approximately 60-70% (HR 0.37,95% CI 0.24-0.58) 3.